The correlation between serum lipid level and epicardial fat thickness in children with growth hormone deficiency

doi:10.3877/cma.j.issn.2095-655X.2018.01.010

Abstract

Abstract:

Objective

To observe the change of epicardial adipose tissue (EAT) thickness in children with growth hormone deficiency(GHD), and explore the effect of growth hormone deficiency on lipid metabolism.

Methods

Using nested case-control study method, 59 patients who were diagnosed with short stature in the Affiliated Hospital of Jining Medical University from January 2017 to October 2017 were selected.According to the growth hormone stimulation test results, all patients were divided into three groups: growth hormone deficiency group (GHmax<0.24 nmol/L) (group A), partial growth hormone deficiency group (0.24 nmol/L≤GHmax<0.47 nmol/L) (group B), normal growth hormone group (GHmax≥0.47 nmol/L) (group C). EAT thickness was tested by echocardiography, meanwhile general information and related results were collected, such as blood lipid, growth hormone, insulin-like growth factor (IGF-1) and bone age etc.

Results

EAT thickness was different in three groups (F=4.13, P<0.05), which was thicker in group A (2.70±0.87)compared with group B(2.20±0.81) and group C(2.00±0.47) (P<0.05), and there was no statistical difference between group B and group C (P>0.05). Smooth curve fitting and threshold effect analysis showed that EAT thickness and triglyceride (TG) were positively correlated (β=2.0, P<0.05), when TG level was higher than 0.9 mmol/L.

Conclusion

EAT thickness is increased in children with GHD and occurrs before abnormality lipid appears.

Key words: Growth hormone deficiency, Epicardial adipose tissue, Lipid metabolism disorders

Yanying Li, Mei Zhang, Shaochun Wang, Dandan Liu, Wenhua Yan, bo Ban. The correlation between serum lipid level and epicardial fat thickness in children with growth hormone deficiency[J]. Chinese Journal of Diagnostics(Electronic Edition), 2018, 06(01): 48-52.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2018.01.010

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2018/V06/I01/48

Figures/Tables 4

References 22

[1]	Molitch ME，Clemmons DR，Malozowski S，et al.Evaluation and treatment of adult growth hormone deficiency：an Endocrine Society Clinical Practice Guideline[J]．Nat Clin Pract Cardiovasc Med，2011，96(6):1587-1609.
[2]	Iacobellis G, Corradi D, Sharma AM.Epicardial adipose tissue：anatomic，biomolecular and clinical relationships with the heart[J]．Nat Clin Pract Cardiovasc Med，2005，2(10):536-543.
[3]	Bertaso AG，Bertol D，Duncan BB，et al.Epicardial fat：definition, measurements and systematic review of main outcomes[J]．Arq Bras Cardiol，2013，101(1):E18-E28.
[4]	刘思思，班博，潘慧，等．济宁地区6～16岁儿童青少年矮小症患病现况研究[J/CD]．中华诊断学电子杂志，2017，5(3):191-194.
[5]	Eroglu S，Sade LE，Yildirir A，et al.Epicardial adipose tissue thickness by echocardiography is a marker for the presence and severity of coronary artery disease[J]．Nutr Metab Cardiovasc Dis, 2009, 19(3):211-217.
[6]	张沫，李昭屏，李卫虹，等．非冠心病胸痛患者心外膜脂肪与冠状动脉血流储备的相关性[J]．北京大学学报(医学版), 2014(6):848-853.
[7]	Gleeson H，Barreto ES，Salvatori R，et al.Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation[J]．Clin Endocrinol (Oxf)，2010，66(4):466-474.
[8]	Rothermel J，Lass N，Bosse C，et al.Impact of discontinuation of growth hormone treatment on lipids and weight status in adolescents[J]．J Pediatr Endocrinol Metab，2017，30(7):749-757.
[9]	De Leonibus C, De Marco S, Stevens A, et al.Growth hormone deficiency in prepubertal children: predictive markers of cardiovascular disease[J]．Horm Res Paediatr，2016，85(6):363-371.
[10]	Johansson JO, Landin K, Tengborn L, et al.High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults[J]．Arterioscler Thromb，1994，14(3):434-437.
[11]	Colao A．The GH-IGF-I axis and the cardiovascular system：clinical implications[J]．Clin Endocrinol (Oxf)，2008，69(3):347-358.
[12]	Davis PH, Dawson JD, Riley WA, et al.Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age：the muscatine study[J]．Circulation，2001，104(23):2815-2819.
[13]	Knop C, Wolters B, Lass N, et al.Carotid intima-media thickness in children treated with growth hormone[J]．J Pediatr Endocrinol Metab，2015，28(9-10):985-991.
[14]	Rothermel J, Reinehr T．Metabolic alterations in paediatric GH deficiency[J]．Best Pract Res Clin Endocrinol Metab，2016，30(6): 757-770.
[15]	Iacobellis G, Leonetti F．Epicardial adipose tissue and insulin resistance in obese subjects[J]．J Clin Endocrinol Metab，2005，90(11):6300.
[16]	Sacks HS，Fain JN.Human epicardial adipose tissue：a review[J]．American Heart Journal，2007，153(6):907-917.
[17]	Iacobellis G．Epicardial adipose tissue in endocrine and metabolic diseases[J]．Endocrine，2014，46(1):8-15.
[18]	Schweizer R，Martin DD，Schönau E，et al.Muscle function improves during growth hormone therapy in short children born small for gestational age: results of a peripheral quantitative computed tomography study on body composition[J]．J Clin Endocrinol Metab，2008，93(8):2978-2983.
[19]	Jørgensen AP, Fougner KJ, Ueland T, et al.Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency[J]．Growth Horm IGF Res，2011，21(2):69-75.
[20]	Khadilkar V, Ekbote V, Kajale N, et al.Effect of one-year growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency[J]．Endocr Res，2014，39(2):74-78.
[21]	Lanes R，Soros AK，Gunczler P，et al.Endothelial function，carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents：apparent effects of growth hormone treatment on these parameters[J]．J Clin Endocrinol Metab，2005，90(7):3978-3982.
[22]	Misra M, Bredella MA, Tsai P, et al.Lower growth hormone and higher cortisol are associated with greater visceral adiposity，intramyocellular lipids, and insulin resistance in overweight girls[J]．Am J Physiol Endocrinol Metab，2008，295(2):385-392.

指标		A组(n＝20)	B组(n＝24)	C组(n＝15)	统计量	P值
年龄(岁，±s)		10.5±2.6	10.4±2.6	10.6±2.8	F＝ 0.04	>0.05
身高(cm，±s)		132.4±13.9	130.0±14.3	134.9±17.0	F＝ 0.49	>0.05
体质量(kg，±s)		34.9±12.1^ab	26.5±6.9	30.7±9.6	F＝ 4.19	<0.05
BMI(kg/m²，±s)		19.3±3.8^ab	15.4±1.9	16.4±1.9	F＝11.61	<0.01
出生体质量(kg，±s)		3.2±0.4	3.2±0.5	3.3±0.4	F＝ 1.71	>0.05
出生身长(cm，±s)		51.4±2.4	49.5±3.0	50.1±0.4	F＝ 0.31	>0.05
父亲身高(cm, ±s)		166.8±5.0	167.4±6.2	168.9±3.1	F＝ 0.68	>0.05
母亲身高(cm, ±s)		155.9±6.3	156.2±5.8	158.6±4.8	F＝ 1.09	>0.05
骨龄(岁，±s)		9.1±3.3	8.8±2.7	9.2±3.6	F＝ 0.06	>0.05
性别(例，%)		?	?	?	χ²＝ 3.23	>0.05
?	男	17(85.0)	15(62.5)	12(80.0)	?	?
?	女	3(15.0)	9(37.5)	3(20.0)	?	?

指标		A组(n＝20)	B组(n＝24)	C组(n＝15)	统计量	P值
年龄(岁，±s)		10.5±2.6	10.4±2.6	10.6±2.8	F＝ 0.04	>0.05
身高(cm，±s)		132.4±13.9	130.0±14.3	134.9±17.0	F＝ 0.49	>0.05
体质量(kg，±s)		34.9±12.1^ab	26.5±6.9	30.7±9.6	F＝ 4.19	<0.05
BMI(kg/m²，±s)		19.3±3.8^ab	15.4±1.9	16.4±1.9	F＝11.61	<0.01
出生体质量(kg，±s)		3.2±0.4	3.2±0.5	3.3±0.4	F＝ 1.71	>0.05
出生身长(cm，±s)		51.4±2.4	49.5±3.0	50.1±0.4	F＝ 0.31	>0.05
父亲身高(cm, ±s)		166.8±5.0	167.4±6.2	168.9±3.1	F＝ 0.68	>0.05
母亲身高(cm, ±s)		155.9±6.3	156.2±5.8	158.6±4.8	F＝ 1.09	>0.05
骨龄(岁，±s)		9.1±3.3	8.8±2.7	9.2±3.6	F＝ 0.06	>0.05
性别(例，%)		?	?	?	χ²＝ 3.23	>0.05
?	男	17(85.0)	15(62.5)	12(80.0)	?	?
?	女	3(15.0)	9(37.5)	3(20.0)	?	?

指标	A组(n＝20)	B组(n＝24)	C组(n＝15)	F值	P值
FBG(mmol/L)	4.60±0.48	4.72±0.49	4.48±0.44	1.21	>0.05
TG(mmol/L)	0.85±0.53	0.72±0.27	0.69±0.21	0.91	>0.05
TC(mmol/L)	4.11±0.62	4.11±0.82	3.69±0.55	2.07	>0.05
LDL(mmol/L)	2.29±0.43	2.23±0.49	2.07±0.49	0.93	>0.05
UA(μmol/L)	261.90±64.31	278.30±67.94	275.00±62.32	0.36	>0.05
IGFBP-3(μg/ml)	4.00±0.71	4.21±1.20	4.10±1.02	0.14	>0.05
IGF-1(μg/L)	181.50±71.69	199.60±89.71	255.70±159.90	2.18	>0.05
L-GHmax(μg/L)	3.03±1.28^ab	6.79±1.71^a	11.65±2.45	97.60	<0.01
In-GHmax(μg/L)	2.24±1.19^ab	4.74±2.38^a	9.73±7.73	13.27	<0.01
EAT厚度(mm)	2.70±0.87^ab	2.20±0.81	2.00±0.47	4.31	<0.05

指标	A组(n＝20)	B组(n＝24)	C组(n＝15)	F值	P值
FBG(mmol/L)	4.60±0.48	4.72±0.49	4.48±0.44	1.21	>0.05
TG(mmol/L)	0.85±0.53	0.72±0.27	0.69±0.21	0.91	>0.05
TC(mmol/L)	4.11±0.62	4.11±0.82	3.69±0.55	2.07	>0.05
LDL(mmol/L)	2.29±0.43	2.23±0.49	2.07±0.49	0.93	>0.05
UA(μmol/L)	261.90±64.31	278.30±67.94	275.00±62.32	0.36	>0.05
IGFBP-3(μg/ml)	4.00±0.71	4.21±1.20	4.10±1.02	0.14	>0.05
IGF-1(μg/L)	181.50±71.69	199.60±89.71	255.70±159.90	2.18	>0.05
L-GHmax(μg/L)	3.03±1.28^ab	6.79±1.71^a	11.65±2.45	97.60	<0.01
In-GHmax(μg/L)	2.24±1.19^ab	4.74±2.38^a	9.73±7.73	13.27	<0.01
EAT厚度(mm)	2.70±0.87^ab	2.20±0.81	2.00±0.47	4.31	<0.05

TG水平的拐点(mmol/L)	β(95%CI)	P值
<0.9	－0.9(－1.8～0.1)	>0.05
≥0.9	2.0(1.2～2.9)	<0.05

Please choose a citation manager

Content to export